



## Clinical trial results:

**A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast Cancer**

### Summary

EudraCT number	2008-002608-25
Trial protocol	AT BE CZ DK
Global end of trial date	09 November 2009

### Results information

Result version number	v1 (current)
This version publication date	22 February 2019
First version publication date	22 February 2019

### Trial information

#### Trial identification

Sponsor protocol code	D0810C00011
-----------------------	-------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	151 85,, Södertälje, Sweden,
Public contact	Clinical Trial Transparency Team, AstraZeneca, ClinicalTrialTransparency@astrazeneca.com
Scientific contact	Clinical Trial Transparency Team, AstraZeneca, ClinicalTrialTransparency@astrazeneca.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 November 2009
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 November 2009
Global end of trial reached?	Yes
Global end of trial date	09 November 2009
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the Phase I part of this study was:

- To establish the appropriate doses of paclitaxel and AZD2281 in combination, based on safety and tolerability (for use in the randomised Phase II part of the study).

The primary objective of the Phase II part of this study was:

- To determine the efficacy (assessed by Progression Free Survival [PFS]) of AZD2281 in combination with paclitaxel compared to paclitaxel alone in this patient population.

Protection of trial subjects:

This study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council on Harmonisation/Good Clinical Practice, applicable regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological Samples.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 September 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	Australia: 12
Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	Belgium: 3
Worldwide total number of subjects	19
EEA total number of subjects	4

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	17
From 65 to 84 years	2
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

In the Phase 1 part of this study, 24 patients were enrolled at 6 centres in 4 countries: Australia (3), Austria (1), Belgium (1) and Canada (1). Protocol Amendment 1 was implemented before recruitment of Cohort 2, which introduced the use of a G-CSF for initial management of neutropenia.

### Pre-assignment

Screening details:

In this trial, there was a screening period of 28 days prior to first dose of study treatment. There were 5 patients who were in the pre-assignment period but were not subsequently assigned treatment. This was due to Progression (1), Incorrect enrolment (3) and Voluntary withdrawal (1).

### Pre-assignment period milestones

Number of subjects started	24 <sup>[1]</sup>
Number of subjects completed	19

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Consent withdrawn by subject: 1
Reason: Number of subjects	Incorrect enrolment: 3
Reason: Number of subjects	Lack of efficacy: 1

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: There were 5 patients who were in the pre-assignment period but were not subsequently assigned treatment. This was due to Progression (1), Incorrect enrolment (3) and Voluntary withdrawal (1).

### Period 1

Period 1 title	Phase I - Safety Run-In (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

The Phase I part of this study is open-label.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cohort 1
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	AZD2281
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

200 mg bd through a 28 day cycle

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

90 mg/m<sup>2</sup> IV for 6 to 10 cycles

<b>Arm title</b>	Cohort 2
------------------	----------

Arm description:

Both arms have the same allocated treatment, however Cohort 2 allowed the use of a granulocyte colony stimulating factor (G-CSF; filgrastim) for initial management of neutropenia

Arm type	Experimental
Investigational medicinal product name	AZD2281
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

200 mg bd through a 28 day cycle

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

90 mg/m<sup>2</sup> IV for 6 to 10 cycles

<b>Number of subjects in period 1</b>	Cohort 1	Cohort 2
Started	9	10
Completed	1	3
Not completed	8	7
Consent withdrawn by subject	1	-
Lack of efficacy	7	7

## Baseline characteristics

### Reporting groups

Reporting group title	Cohort 1
-----------------------	----------

Reporting group description: -
--------------------------------

Reporting group title	Cohort 2
-----------------------	----------

Reporting group description:
------------------------------

Both arms have the same allocated treatment, however Cohort 2 allowed the use of a granulocyte colony stimulating factor (G-CSF; filgrastim) for initial management of neutropenia
--

Reporting group values	Cohort 1	Cohort 2	Total
Number of subjects	9	10	19
Age Categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	8	9	17
From 65-84 years	1	1	2
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	50.0	50.7	
standard deviation	± 11.5	± 8.2	-
Gender Categorical			
Units: Subjects			
Female	9	10	19
Male	0	0	0
Race			
Units: Subjects			
White	9	10	19
Age			
Units: years			
median	49.0	49.5	
full range (min-max)	36 to 71	38 to 67	-

### Subject analysis sets

Subject analysis set title	FAS
----------------------------	-----

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:
-----------------------------------

Includes all patients eligible to be dosed
--

<b>Reporting group values</b>	FAS		
Number of subjects	19		
Age Categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	17		
From 65-84 years	2		
85 years and over	0		
Age Continuous			
Units: years			
arithmetic mean	50.4		
standard deviation	± 9.6		
Gender Categorical			
Units: Subjects			
Female	19		
Male	0		
Race			
Units: Subjects			
White	19		
Age			
Units: years			
median	49.0		
full range (min-max)	36 to 71		

## End points

### End points reporting groups

Reporting group title	Cohort 1
Reporting group description: -	
Reporting group title	Cohort 2
Reporting group description:	
Both arms have the same allocated treatment, however Cohort 2 allowed the use of a granulocyte colony stimulating factor (G-CSF; filgrastim) for initial management of neutropenia	
Subject analysis set title	FAS
Subject analysis set type	Full analysis
Subject analysis set description:	
Includes all patients eligible to be dosed	

### Primary: Patients with At Least One Adverse Event

End point title	Patients with At Least One Adverse Event <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe:	
From signing of ICF throughout treatment period up to and including 30-day follow-up period.	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data	

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects				
Number of Patients	9	10		
Percentage	100	100		

### Statistical analyses

No statistical analyses for this end point

### Primary: Patients with At Least One Adverse Event Causally Related to Olaparib

End point title	Patients with At Least One Adverse Event Causally Related to Olaparib <sup>[2]</sup>
End point description:	
End point type	Primary
End point timeframe:	
From signing of ICF throughout treatment period up to and including 30-day follow-up period.	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects				
Number of Patients	7	9		

## Statistical analyses

No statistical analyses for this end point

### Primary: Patients with At Least One Adverse Event Causally Related to Paclitaxel

End point title	Patients with At Least One Adverse Event Causally Related to Paclitaxel <sup>[3]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From signing of ICF throughout treatment period up to and including 30-day follow-up period.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects	9	10		

## Statistical analyses

No statistical analyses for this end point

### Primary: Patients with At Least One Adverse Event of CTCAE Grade 3 or Higher

End point title	Patients with At Least One Adverse Event of CTCAE Grade 3 or Higher <sup>[4]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From signing of ICF throughout treatment period up to and including 30-day follow-up period.

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects	8	5		

## Statistical analyses

No statistical analyses for this end point

### Primary: Patients with At Least One Adverse Event with Outcome Death

End point title	Patients with At Least One Adverse Event with Outcome
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From signing of ICF throughout treatment period up to and including 30-day follow-up period.

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Patients with At Least One Serious Adverse Event

End point title	Patients with At Least One Serious Adverse Event <sup>[6]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From signing of ICF throughout treatment period up to and including 30-day follow-up period.

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects	2	4		

## Statistical analyses

No statistical analyses for this end point

### Primary: Patients with At Least One Adverse Event Leading to Discontinuation of IP

End point title	Patients with At Least One Adverse Event Leading to Discontinuation of IP <sup>[7]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From signing of ICF throughout treatment period up to and including 30-day follow-up period.

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with $\geq 2$ CTC grade changes from baseline for haematology parameters

End point title	Number of patients with $\geq 2$ CTC grade changes from baseline for haematology parameters <sup>[8]</sup>
-----------------	--

End point description:

Baseline is defined as the last result obtained prior to the start of study treatment.

End point type	Primary
----------------	---------

End point timeframe:

Derived from lab assessments between the start of treatment and 30 days following the date of last dose of study medication.

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects				
Leucocytes	9	6		
Neutrophils	7	6		
Lymphocytes	4	4		
Platelets	1	1		
aPTT	2	1		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of patients with CTC grade changes to 3 or 4 from baseline for haematology parameters

End point title	Number of patients with CTC grade changes to 3 or 4 from baseline for haematology parameters <sup>[9]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Derived from lab assessments between the start of treatment and 30 days following the date of last dose of study medication.

Baseline is defined as the last result obtained prior to the start of study treatment.

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects				
Leucocytes	3	3		
Neutrophils	2	3		
Lymphocytes	4	3		
Platelets	1	0		
aPTT	1	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with $\geq 2$ CTC grade changes from baseline for clinical chemistry parameters

End point title	Number of patients with $\geq 2$ CTC grade changes from baseline for clinical chemistry parameters <sup>[10]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Derived from lab assessments between the start of treatment and 30 days following the date of last dose of study medication.

Baseline is defined as the last result obtained prior to the start of study treatment.

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	10		
Units: Subjects				
ALT	0	1		
AST	0	0		
$\gamma$ -GT	3	1		
Total bilirubin	0	1		
ALP	0	0		
Albumin	0	1		
Amylase	0	0		
Lipase	0	3		
Creatinine	1	0		
Glucose (low)	0	0		
Glucose (high)	4	1		
Calcium (low)	0	0		
Calcium (high)	0	0		
Magnesium (low)	0	0		
Magnesium (high)	0	0		
Potassium (low)	0	0		
Potassium (high)	2	0		
Sodium (low)	2	2		
Sodium (high)	0	1		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of patients with CTC grade changes to 3 or 4 from baseline for clinical chemistry parameters

End point title	Number of patients with CTC grade changes to 3 or 4 from baseline for clinical chemistry parameters <sup>[11]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Derived from lab assessments between the start of treatment and 30 days following the date of last dose of study medication.

Baseline is defined as the last result obtained prior to the start of study treatment.

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This study was terminated prematurely and therefore there was no formal statistical analysis of safety and tolerability data

End point values	Cohort 1	Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9 <sup>[12]</sup>	10 <sup>[13]</sup>		
Units: Subjects				
ALT	0	2		
AST	0	2		
γ-GT	1	3		
Total bilirubin	0	1		
ALP	0	1		
Albumin	0	0		
Amylase	0	1		
Lipase	0	1		
Creatinine	0	0		
Glucose (low)	0	0		
Glucose (high)	3	1		
Calcium (low)	0	0		
Calcium (high)	0	0		
Magnesium (low)	0	0		
Magnesium (high)	0	0		
Potassium (low)	0	0		
Potassium (high)	1	0		
Sodium (low)	2	2		
Sodium (high)	0	1		

Notes:

[12] - 1 patient had a Grade 4 CTC elevation in γ-GT at baseline with no change to max severity is excluded

[13] - 1 patient had a Grade 4 CTC elevation in γ-GT at baseline with no change to max severity is excluded

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug until last study visit

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	13.0
--------------------	------

### Reporting groups

Reporting group title	200mg bd - Cohort 2
-----------------------	---------------------

Reporting group description: -

Reporting group title	200mg bd - Cohort 1
-----------------------	---------------------

Reporting group description: -

Serious adverse events	200mg bd - Cohort 2	200mg bd - Cohort 1	
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 10 (40.00%)	2 / 9 (22.22%)	
number of deaths (all causes)	0	1	
number of deaths resulting from adverse events	0	0	
Vascular disorders			
DEEP VEIN THROMBOSIS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
HAEMODYNAMIC INSTABILITY			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
APHASIA			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
FEBRILE NEUTROPENIA			

subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
PYREXIA			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
CELLULITIS			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEVICE RELATED INFECTION			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INFECTION			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	200mg bd - Cohort 2	200mg bd - Cohort 1	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	9 / 9 (100.00%)	
Vascular disorders			
DEEP VEIN THROMBOSIS			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
HOT FLUSH			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	
occurrences (all)	1	2	

HYPERTENSION			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
HYPOTENSION			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
LYMPHOEDEMA			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	
occurrences (all)	2	1	
THROMBOPHLEBITIS SUPERFICIAL			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
ASTHENIA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
CHILLS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
FATIGUE			
subjects affected / exposed	4 / 10 (40.00%)	7 / 9 (77.78%)	
occurrences (all)	4	9	
FEELING COLD			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
INFLUENZA LIKE ILLNESS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
MALAISE			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	
occurrences (all)	0	2	
OEDEMA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
OEDEMA PERIPHERAL			

subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	1 / 9 (11.11%) 1	
PYREXIA subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 9 (22.22%) 2	
THROMBOSIS IN DEVICE subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Reproductive system and breast disorders BREAST PAIN subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
VULVOVAGINAL DISCOMFORT subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders COUGH subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	3 / 9 (33.33%) 3	
DYSPHONIA subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
DYSPNOEA subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 3	3 / 9 (33.33%) 4	
EPISTAXIS subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 4	2 / 9 (22.22%) 2	
OROPHARYNGEAL PAIN subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 3	2 / 9 (22.22%) 2	
PLEURAL EFFUSION subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
PRODUCTIVE COUGH			

subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	
occurrences (all)	0	2	
RHINORRHOEA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
Psychiatric disorders			
ANXIETY			
subjects affected / exposed	1 / 10 (10.00%)	3 / 9 (33.33%)	
occurrences (all)	1	3	
CONFUSIONAL STATE			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
DEPRESSION			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
INSOMNIA			
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)	
occurrences (all)	2	1	
MOOD ALTERED			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Investigations			
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
BLOOD ALKALINE PHOSPHATASE INCREASED			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
BLOOD BILIRUBIN INCREASED			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
BLOOD LACTATE DEHYDROGENASE			

ABNORMAL			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
GAMMA-GLUTAMYLTRANSFERASE ABNORMAL			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
WEIGHT INCREASED			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
Cardiac disorders			
PALPITATIONS			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
TACHYCARDIA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
Nervous system disorders			
APHONIA			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
ATAXIA			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
COGNITIVE DISORDER			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
DIZZINESS			
subjects affected / exposed	0 / 10 (0.00%)	3 / 9 (33.33%)	
occurrences (all)	0	3	
DYSGEUSIA			
subjects affected / exposed	3 / 10 (30.00%)	2 / 9 (22.22%)	
occurrences (all)	3	2	
HEADACHE			
subjects affected / exposed	2 / 10 (20.00%)	3 / 9 (33.33%)	
occurrences (all)	2	4	
HYPOAESTHESIA			

subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
LETHARGY			
subjects affected / exposed	3 / 10 (30.00%)	2 / 9 (22.22%)	
occurrences (all)	3	2	
MIGRAINE			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
NEUROPATHY PERIPHERAL			
subjects affected / exposed	3 / 10 (30.00%)	3 / 9 (33.33%)	
occurrences (all)	3	3	
PARAESTHESIA			
subjects affected / exposed	0 / 10 (0.00%)	3 / 9 (33.33%)	
occurrences (all)	0	3	
PERIPHERAL SENSORY NEUROPATHY			
subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	
occurrences (all)	2	2	
SENSORY LOSS			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	
occurrences (all)	1	1	
SYNCOPE			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
TREMOR			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
ANAEMIA			
subjects affected / exposed	1 / 10 (10.00%)	5 / 9 (55.56%)	
occurrences (all)	1	11	
LEUKOPENIA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	4	
LYMPH NODE PAIN			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	

NEUTROPENIA subjects affected / exposed occurrences (all)	4 / 10 (40.00%) 9	7 / 9 (77.78%) 22	
Ear and labyrinth disorders TINNITUS subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
VERTIGO subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
Eye disorders DARK CIRCLES UNDER EYES subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
DRY EYE subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 9 (11.11%) 1	
EYE PAIN subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
EYE SWELLING subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
LACRIMATION INCREASED subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
VISION BLURRED subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	2 / 9 (22.22%) 2	
Gastrointestinal disorders ABDOMINAL DISCOMFORT subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 9 (0.00%) 0	
ABDOMINAL PAIN subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	3 / 9 (33.33%) 3	
ABDOMINAL DISTENSION			

subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	2
ABDOMINAL PAIN UPPER		
subjects affected / exposed	1 / 10 (10.00%)	4 / 9 (44.44%)
occurrences (all)	1	5
ABDOMINAL WALL HAEMATOMA		
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	1
CONSTIPATION		
subjects affected / exposed	2 / 10 (20.00%)	4 / 9 (44.44%)
occurrences (all)	2	5
DENTAL CARIES		
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	1
DIARRHOEA		
subjects affected / exposed	6 / 10 (60.00%)	6 / 9 (66.67%)
occurrences (all)	6	7
DRY MOUTH		
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)
occurrences (all)	1	1
DYSPEPSIA		
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	1
GASTRITIS		
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)
occurrences (all)	1	0
GASTROOESOPHAGEAL REFLUX DISEASE		
subjects affected / exposed	2 / 10 (20.00%)	1 / 9 (11.11%)
occurrences (all)	3	1
HAEMORRHOIDS		
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	1
MOUTH ULCERATION		
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)
occurrences (all)	1	0

NAUSEA			
subjects affected / exposed	6 / 10 (60.00%)	6 / 9 (66.67%)	
occurrences (all)	7	11	
STOMATITIS			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	
occurrences (all)	2	4	
VOMITING			
subjects affected / exposed	3 / 10 (30.00%)	3 / 9 (33.33%)	
occurrences (all)	4	5	
Hepatobiliary disorders			
HEPATIC PAIN			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
ACNE			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
ALOPECIA			
subjects affected / exposed	4 / 10 (40.00%)	7 / 9 (77.78%)	
occurrences (all)	4	9	
DERMATITIS ACNEIFORM			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
ERYTHEMA			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
HYPERHIDROSIS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
NAIL DISORDER			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	
occurrences (all)	1	2	
NIGHT SWEATS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
PRURITUS			

subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	2 / 9 (22.22%) 2	
RASH subjects affected / exposed occurrences (all)	5 / 10 (50.00%) 8	1 / 9 (11.11%) 1	
SKIN DISORDER subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
Renal and urinary disorders			
ANURIA subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
DYSURIA subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
HAEMATURIA subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
POLAKIURIA subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
RENAL FAILURE subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
STRESS URINARY INCONTINENCE subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 9 (11.11%) 1	
URINARY RETENTION subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 9 (11.11%) 1	
Musculoskeletal and connective tissue disorders			
ARTHRALGIA subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	2 / 9 (22.22%) 4	
ARTHRITIS			

subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
BACK PAIN			
subjects affected / exposed	4 / 10 (40.00%)	2 / 9 (22.22%)	
occurrences (all)	4	2	
BONE PAIN			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	2	
MUSCLE SPASMS			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	
occurrences (all)	0	2	
MUSCLE TIGHTNESS			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
MUSCULAR WEAKNESS			
subjects affected / exposed	0 / 10 (0.00%)	2 / 9 (22.22%)	
occurrences (all)	0	2	
MUSCULOSKELETAL CHEST PAIN			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	
occurrences (all)	1	3	
MUSCULOSKELETAL PAIN			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
MUSCULOSKELETAL STIFFNESS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
MYALGIA			
subjects affected / exposed	2 / 10 (20.00%)	4 / 9 (44.44%)	
occurrences (all)	2	4	
NECK PAIN			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
PAIN IN EXTREMITY			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	
occurrences (all)	1	2	
Infections and infestations			

CYSTITIS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
DEVICE RELATED INFECTION			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
HERPES ZOSTER			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	2 / 10 (20.00%)	0 / 9 (0.00%)	
occurrences (all)	2	0	
NASOPHARYNGITIS			
subjects affected / exposed	1 / 10 (10.00%)	2 / 9 (22.22%)	
occurrences (all)	1	3	
SINUSITIS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
SKIN INFECTION			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
UPPER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	3 / 10 (30.00%)	2 / 9 (22.22%)	
occurrences (all)	5	4	
URINARY TRACT INFECTION			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
VIRAL PHARYNGITIS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
Metabolism and nutrition disorders			
ACIDOSIS			
subjects affected / exposed	0 / 10 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
DECREASED APPETITE			

subjects affected / exposed	2 / 10 (20.00%)	2 / 9 (22.22%)	
occurrences (all)	2	3	
DEHYDRATION			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
HYPERGLYCAEMIA			
subjects affected / exposed	1 / 10 (10.00%)	1 / 9 (11.11%)	
occurrences (all)	1	1	
HYPOKALAEMIA			
subjects affected / exposed	1 / 10 (10.00%)	0 / 9 (0.00%)	
occurrences (all)	1	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 January 2009	Addresses dose modifications, introducing in a step-wise approach the addition of granulocyte-colony stimulating factor (G-CSF) support (Cohort 2)
17 March 2009	Changes to Phase II part of the trial: Giving patients the possibility to receive maximum tolerated dose of Olaparib on monotherapy, removing requirement for BRCA testing and incorporating a single interim analysis of progression free survival
04 August 2009	Addresses the study closure, the management of Phase I patients currently receiving study treatment, and the definition of end of study given the decision not to proceed to Phase II.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported